Balancing Blood Product Wastage and Patient Safety: Primum Non Nocere
- PMID: 39423911
- DOI: 10.1016/j.jpeds.2024.114340
Balancing Blood Product Wastage and Patient Safety: Primum Non Nocere
Conflict of interest statement
Declaration of Competing Interest Derek de Winter, PhD-program funded by Momenta Pharmaceuticals, Inc, which was acquired by Johnson & Johnson, and is an investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN. E.J.T. (Joanne) Verweij is the principal investigator for a phase 2 trial (NCT03842189) and a phase 3 trial (NCT05912517) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals. Enrico Lopriore is a sub-investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals. All other authors reported to have no conflict of interest or financial disclosures.
Publication types
LinkOut - more resources
Full Text Sources